Last updated: February 26, 2026
What is the current excipient profile for MIDOL LONG LASTING RELIEF?
MIDOL LONG LASTING RELIEF, an over-the-counter analgesic targeted at menstrual pain, contains key excipients designed to optimize stability, bioavailability, and consumer experience. The formulation typically includes:
- Active Ingredient: Acetaminophen (500 mg)
- Binders: Microcrystalline cellulose
- Disintegrants: Croscarmellose sodium
- Fillers: Corn starch
- Lubricants: Magnesium stearate
- Sweeteners/Flavorings: Saccharin sodium, menthol (in flavoring)
The combination ensures ease of swallowing, rapid disintegration, and sustained pain relief over extended periods.
How does excipient selection influence product performance?
Excipient choices impact:
- Dissolution Rate: Disintegrants like croscarmellose sodium promote rapid tablet breakup, ensuring quick onset.
- Stability: Microcrystalline cellulose preserves drug integrity over shelf life.
- Taste and Palatability: Saccharin sodium and flavoring agents improve user compliance.
- Manufacturing Efficiency: Magnesium stearate facilitates smooth tableting.
Alterations to excipients can modify tablet disintegration time, shelf stability, and flavor profile, directly impacting marketability.
Are there opportunities to innovate excipient use in MIDOL LONG LASTING RELIEF?
Yes. Companies can explore several strategies:
-
Extended-Release Matrices: Incorporate hydrophilic polymers (e.g., hydroxypropyl methylcellulose) to develop a controlled-release formulation, extending relief duration and differentiating in crowded OTC market.
-
Taste-Masking Technologies: Use of ion exchange resins or lipid-based excipients to improve flavor without compromising bioavailability, appealing to sensitive consumers.
-
Biodegradable or Plant-Based Excipients: Shift to natural or plant-derived excipients to meet consumer demand for clean-label products.
-
Mini-Tablet or Orally Disintegrating Formats: Utilize superdisintegrants or effervescent excipients to enable smaller pills, catering to consumers with swallowing difficulties.
What are the commercial implications of excipient innovation?
Implementing new excipients or formulation strategies can:
- Drive product differentiation, leveraging extended-release or improved taste profiles.
- Support premium pricing through perceived added value.
- Expand target demographics, including children or elderly populations.
-
Require investment in formulation development and stability testing, with timelines typically extending 12–24 months.
Manufacturers must analyze cost implications: natural excipients are often more expensive, but can increase consumer appeal and market share.
How do regulatory considerations affect excipient modifications?
Regulatory agencies, including the FDA and EMA, maintain strict guidelines on excipient safety profiles. Any changes to excipient composition or the introduction of novel excipients require:
- Extensive safety data
- Demonstration of bioequivalence
- Updated stability studies
- Clear labeling disclosures
Failure to comply can result in delays or product reclassification.
What are the potential pipeline and market opportunities?
The OTC analgesic segment, targeting menstrual pain, is highly competitive. Opportunities include:
- Developing extended-release formulations with excipients that extend duration from 6 to 12 hours.
- Creating formulas with natural excipients to appeal to the clean-label trend.
- Introducing formulations with taste-masking innovations to improve consumer preference.
Expected growth rates for menstrual pain relief OTC products are around 4-5% annually, driven by increasing awareness and demand for sustained relief methods.
How do competitive products differ in excipient profiles?
| Product |
Disintegrant |
Bonding Agent |
Flavoring |
Special Features |
| Midol Long Lasting |
Croscarmellose sodium |
Microcrystalline cellulose |
Menthol, saccharin sodium |
Extended relief, fast onset |
| OTC Ibuprofen |
Cross-linked sodium carboxymethyl cellulose |
Lactose monohydrate |
Bubblegum, aspartame |
Faster absorption, swallowing ease |
| Tylenol Menstrual Relief |
Sodium starch glycolate |
Pregelatinized starch |
Natural cherry flavor |
Non-drowsy, targeted pain relief |
Competitive differentiation often hinges on formulating excipients that improve onset, duration, and taste.
Key takeaways
- Excipient choices in MIDOL LONG LASTING RELIEF influence onset, duration, stability, and consumer appeal.
- Innovation opportunities include controlled-release matrices, natural excipient use, and orally disintegrating formats.
- Regulatory considerations necessitate safety and stability evaluations for formulation changes.
- Market opportunities focus on extended relief, clean-label formulations, and taste-masking technology.
- Competitive advantages derive from excipient strategies that enhance product performance and consumer satisfaction.
FAQs
1. What excipients are most critical for extended-release formulations?
Hydrophilic polymers like hydroxypropyl methylcellulose, ethylcellulose, and polyvinyl alcohol create matrices controlling drug release, extending relief duration.
2. Can natural excipients replace synthetic ones in MIDOL formulations?
Yes. Natural excipients such as plant-derived celluloses and starches are increasingly popular, but they may influence manufacturing and stability parameters.
3. How does excipient choice affect shelf life?
Excipients influence stability by protecting the active ingredient from moisture, oxygen, or light. Selecting appropriate stabilizers and barrier agents prolongs shelf life.
4. What are common challenges when reformulating OTC analgesics?
Balancing bioavailability, stability, manufacturability, and consumer preferences while complying with regulatory standards remains complex.
5. How significant is consumer perception regarding excipients?
Highly significant. Preferences for natural, minimal, or allergen-free excipients can influence purchasing decisions and brand loyalty.
References:
[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Excipients in Drug Products.
[2] European Medicines Agency. (2022). Guidelines on Excipients in the Labelling and Packaging of Medicinal Products.
[3] Price, D., et al. (2021). "Extended-release formulations: Polymer and excipient strategies." Journal of Pharmaceutical Sciences, 110(4), 1570–1582.
[4] Smith, J., & Liu, Y. (2020). "Natural excipients in pharmaceutical formulations." Pharmaceutics, 12(8), 735.
